SPTLC3 and Insulin resistance: To the best of our knowledge, our study is the first to suggest that therapeutically targeting ceramide synthesis through inhibiting SPTLC3 could be an effective treatment for insulin resistance, and SFA may be a potential candidate for prevention and amelioration of hepatic insulin resistance via a ceramide-dependent mechanism.